OncoMatch/Clinical Trials/NCT07182526
Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome
Is NCT07182526 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Quercetin and Alpha Lipoic Acid 600 MG Oral Tablet for pcos (polycystic ovary syndrome) of bilateral ovaries.
Treatment: Quercetin · Alpha Lipoic Acid 600 MG Oral Tablet · MetFORMIN 500 Mg Oral Tablet — This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: oral contraceptives
Cannot have received: hormonal therapy
Cannot have received: anti-lipidemic drugs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify